Companion Diagnostics Market

Companion Diagnostics Market by Product (Assays, Kits, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Blood, Lung, Colorectal Cancer, Neurology Diseases), End User (Pharma Companies, CROs), Region - Global Forecast to 2026

Report Code: MD 5463 Feb, 2022, by marketsandmarkets.com

[331 Pages Report] The global Companion Diagnostics Market is projected to reach USD 9.9 billion by 2026 from USD 5.5 billion in 2021, at a CAGR of 12.6% during the forecast period. Market growth is driven by factors such as the growing significance of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies.

Companion Diagnostics Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on Global Companion diagnostics Market

The emergence of the COVID-19 pandemic has changed the delivery of medical care across the world. The increased pressure due to the growing rate of hospitalization of COVID-19 patients had led to the re-profiling of many hospitals and departments for treating patients with COVID-19. The COVID-19 outbreak led to curfews and lockdown worldwide, leading to many diagnostic and treatment procedures had been cancelled or postponed around the world, including as many as 2.3 million cancer surgeries according to one study. Clinical trials in oncology have also been affected, with about 170 studies suspended due to Covid-19, according to a report by Evaluate Vantage. It has mild-moderately affected the growth of the companion diagnostics market. As stringencies with respect to curfews and social distancing become more liberal, the demand is expected to grow, creating a deficit in the market. However, a resurgence in testing numbers is being seen as countries gradually ease restrictions on movement.

Moreover, the demand for companion diagnostic tests is on the rise for the early detection and screening of chronic diseases. These tests also help reduce the side-effects of drugs, improve patient outcomes, provide high diagnostic accuracy and specificity, reduce pharmacotherapy variability, and identify the most-effective targeted therapy options. They are also associated with higher drug development success.

Market Dynamics

Driver: Growing need for targeted medicines

With advances in genetic sequencing and genomics, it is now widely believed that drugs can show varying outcomes in different individuals. A better understanding of the genetic characteristics or biomarkers of an individual can promote the practice of administering ‘the right drug, at the right time, at the right dose, for the right person’. Pharmaceutical and biopharmaceutical companies are continuously attempting to implement patient-selection diagnostic frameworks in the earlier stages of drug development to provide targeted therapies to the right candidate. This further supports the growth of the companion diagnostics market.

Opportunity: Increasing demand for next-generation sequencing

NGS-based companion diagnostic tests aim to unlock molecular information from each patient's tumor genome to guide treatment decisions for cancer therapies. Next-generation sequencing detects multiple biomarkers for multiple drug therapies in a shorter time frame as compared to other sequencing techniques. The use of NGS panels for biomarker measurement in one test has the potential to help in the treatment of many different types of cancers. The various technological advancements in NGS also provide market players with an immediate competitive edge over players providing other technologies such as PCR, ICH, and ISH. As a result, major market players are focusing on developing companion diagnostic products based on NGS.

Restraint: High cost of immunotherapy treatment

While immunotherapy has shown significant promise in cancer treatment, its high cost has limited overall patient access. Physicians might instead find it best to combine therapies; this, in turn, might extend the duration of the treatment from five months to over three years. In this case, the longer the duration, the greater the expense. In addition, the cost of personalized immunotherapies is high. For example, KYMRIAH, the approved CAR T-cell treatment from Novartis, and YESCARTA, from Gilead Sciences, costs between USD 373,000 and USD 475,000 per patient, depending on the type of cancer being treated. Each CAR T-cell treatment is designed specifically for the patient, utilizing substantial lab resources. Thus, the cost for just the drug goes up to about USD 60,000 per patient. The cost of cancer immunotherapies can far exceed the cost required for other therapy options, such as chemotherapy or radiation therapy. Thus, the high cost of immuno-oncology therapies is expected to hamper the growth of companion diagnostics market.

Challenge: Lack of awareness of companion diagnostics testing

It is important to build awareness amongst patients, clinicians, and the public regarding the importance of clinical trials. To improve awareness among clinicians, providing special access to reputable, evidence-based latest information on these new cancer medicines can be helpful. To improve public awareness, increasing access to a common and trusted source of truth is necessary. Several publishing houses and industry players provide monthly journals and information leaflets. Stakeholders have also focused on awareness initiatives to ensure patients and providers can access and understand the benefits of companion diagnostics.

The companion diagnostics market is highly consolidated. The top players—F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Qiagen N.V. (Germany), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories, Inc. (US) -in the companion diagnostics market accounted for a combined majority market share in 2020. There is a high degree of competition among the market players. Only major companies can afford high-capital investments as well as the high cost of R&D and manufacturing. This will prevent new entrants from entering this market.

“In 2020, assays, kits & reagents segment accounted for the largest share of the companion diagnostics market, by product & service.”

The companion diagnostics market is segmented into assays, kits & reagents, and software & services. The assays, kits & reagents accounted for the largest share of the companion diagnostics market in 2020, mainly due to the the availability of a wide range of products, and increasing use of assays and kits in different therapeutic areas.

“In 2020, PCR segment accounted for the largest share in the market, by technology.”

The companion diagnostics market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), in situ hybridization (ISH), immunohistochemistry (IHC), and other technologies. In 2020, the PCR segment accounted for the largest share of the companion diagnostics market. Factors such as the ease of use and widespread availability of PCR kits & reagents in companion diagnostic testing, and growing applications of PCR in the high-throughput detection of mutants with a limited or low allele frequency of genes.

“ In 2020, cancer segment accounted for the largest share in the market, by indication.”

The companion diagnostics market is segmented into cancer, cardiovascular diseases (CVDs), neurological diseases, infectious diseases, and other indications (inflammatory and inherited diseases, among others). In 2020, the cancer segment accounted for the largest share of the companion diagnostics market. Factors such as growing role of companion diagnostics in the personalized medicine treatment for cancer, and increasing utility of biomarkers in the diagnosis of cancer.

“In 2020, pharmaceutical & biotechnology companies and reference laboratories segment accounted for the largest share in the market, by end user.”

The companion diagnostics market is segmented into pharmaceutical & biotechnology companies, reference laboratories, CROs, and other end users (including physician & hospital laboratories, and academic medical centers). In 2020, pharmaceutical & biotechnology companies accounted for a larger share of the companion diagnostics market. The growing use of companion diagnostics owing to their increasing prominence in drug development, and the increasing importance of companion diagnostic biomarkers.

“North America is the largest regional market for companion diagnostics.”

The global companion diagnostics market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the companion diagnostics market. The North American companion diagnostics market growth can be attributed to the presence of many leading companion diagnostics vendors & national clinical laboratories, the easy accessibility to technologically advanced devices and instruments, and the highly developed healthcare system in the US and Canada.

Companion Diagnostics Market  by Region

To know about the assumptions considered for the study, download the pdf brochure

Some key players in the companion diagnostics market (2021- 2026)

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2017–2026

Base year considered

2020

Forecast period

2017-2020 & 2021–2026

Forecast units

Value (USD)

Segments covered

Product & service, technology, indication, end user, and region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Companies covered

F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Qiagen N.V. (Germany), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina Inc. (US), bioM้rieux SA (France), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Abnova Corporation (Taiwan), Guardant Health, Inc. (US), ICON Plc (Ireland), BioGenex Laboratories, Inc. (US), Invivoscribe Technologies (US), ArcherDX, Inc. (US), NG Biotech (France), Qฒ Solutions (US), Amoy Diagnostics Co., Ltd. (China), Abacus Diagnostica Oy (Finland), Asuragen Inc. (US), SAGA Diagnostics (Sweden), Meso Scale Diagnostics, LLC. (US), and Creative Biolabs (US)

This report categorizes the companion diagnostics market into the following segments and subsegments:

By Product & Service

  • Assays, Kits & Reagents
  • Software & Services

By Technology

  • Polymerase Chain Reaction
  • Next-generation Sequencing
  • In Situ Hybridization
  • Immunohistochemistry
  • Other Technologies

By Indication

  • Cancer `
    • Lung Cancer
    • Breast Cancer
    • Blood Cancer
    • Colorectal Cancer
    • Other Cancer Types
  • Neurological Disorders
  • Cardiovascular Diseases
  • Infectious Diseases
  • Other Indications

By End User

  • Pharmaceutical & Biopharmaceutical Companies
  • Reference Laboratories
  • Contract Research Organizations
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • Switzerland
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

Recent Developments

  • In May 2021, Qiagen N.V. (Germany) expanded the therascreen KRAS Kit.
  • In April 2019, Roche Diagnostics (Switzerland) acquired TIB Molbiol Group (Germany). This acquisition will enhance Roche’s broad portfolio of molecular diagnostics solutions with a wide range of assays for infectious diseases, such as identifying SARS-CoV-2 variants.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 28)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
    1.3 MARKETS COVERED
           FIGURE 1 COMPANION DIAGNOSTICS MARKET SEGMENTATION
           1.3.1 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 32)
    2.1 RESEARCH DATA
           FIGURE 2 COMPANION DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    2.1.2.1 Primary sources
                    2.1.2.2 Key data from primary sources
                    2.1.2.3 Key industry insights
                               FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
           2.2.1 BOTTOM-UP APPROACH
                    2.2.1.1 Approach 1: Company revenue estimation approach
                               FIGURE 4 COMPANION DIAGNOSTICS MARKET: BOTTOM-UP APPROACH
                    2.2.1.2 Approach 2: Presentations of companies and primary interviews
                    2.2.1.3 Growth forecast (2021–2026)
                    2.2.1.4 CAGR projections
                               FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.2.2 TOP-DOWN APPROACH
                    FIGURE 6 COMPANION DIAGNOSTICS MARKET: TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN & DATA TRIANGULATION
           FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ANALYSIS
    2.5 ASSUMPTIONS FOR THE STUDY
    2.6 LIMITATIONS
    2.7 RISK ASSESSMENT
           2.7.1 RISK ASSESSMENT: COMPANION DIAGNOSTICS MARKET
    2.8 GROWTH RATE ASSUMPTIONS
    2.9 COVID-19 HEALTH ASSESSMENT
    2.10 COVID-19 ECONOMIC ASSESSMENT
    2.11 ASSESSMENT OF IMPACT OF COVID-19 ON ECONOMIC SCENARIO
                    FIGURE 8 CRITERIA IMPACTING GLOBAL ECONOMY
                    FIGURE 9 RECOVERY SCENARIO OF GLOBAL ECONOMY
    2.12 ASSESSMENT OF IMPACT OF COVID-19 ON ECONOMIC SCENARIO IN COMPANION DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY (Page No. - 48)
    FIGURE 10 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
    FIGURE 11 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
    FIGURE 12 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION)
    FIGURE 13 COMPANION DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    FIGURE 14 COMPANION DIAGNOSTICS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 52)
    4.1 COMPANION DIAGNOSTICS MARKET OVERVIEW
           FIGURE 15 GROWING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
    4.2 COMPANION DIAGNOSTICS MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026
           FIGURE 16 ASSAYS, KITS & REAGENTS SEGMENT TO DOMINATE MARKET IN 2026
    4.3 COMPANION DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026
           FIGURE 17 POLYMERASE CHAN REACTION SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
    4.4 COMPANION DIAGNOSTICS MARKET SHARE, BY INDICATION, 2021 VS. 2026
           FIGURE 18 CANCER SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
    4.5 COMPANION DIAGNOSTICS MARKET SHARE, BY END USER, 2021 VS. 2026
           FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO LEAD MARKET IN 2026
    4.6 COMPANION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN COMPANION DIAGNOSTICS MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 56)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 21 COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Advantages of companion diagnostics
                               5.2.1.1.1 Growing need for targeted therapy
                               5.2.1.1.2 Rising importance of personalized medicine
                               FIGURE 22 GLOBAL LAUNCH OF PERSONALIZED MEDICINE PRODUCTS, 2008-2020
                               FIGURE 23 GROWTH IN US FDA PERSONALIZED MEDICINE APPROVAL RATE, 2015–2020
                               5.2.1.1.3 Increasing global incidence of cancer
                               FIGURE 24 GLOBAL CANCER INCIDENCE, 2008-2030
                               5.2.1.1.4 Growing application areas of companion diagnostics
           5.2.2 RESTRAINTS
                    5.2.2.1 High capital investment and low cost-benefit ratio
                    5.2.2.2 Expensive companion diagnostic tests
                    5.2.2.3 Uncertain reimbursement scenario in different regions
                               TABLE 1 COMPANION DIAGNOSTICS REIMBURSEMENT SCENARIO WORLDWIDE
                    5.2.2.4 High cost of immunotherapy treatment
                               TABLE 2 COST OF KEYTRUDA, BY REGION (2018)
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increasing demand for next-generation sequencing
                               TABLE 3 PARTNERSHIPS & COLLABORATIONS FOR DEVELOPING NGS-BASED COMPANION DIAGNOSTIC TESTS
                    5.2.3.2 Growing significance of companion diagnostics in drug development
                    5.2.3.3 Higher number of clinical trials
                               TABLE 4 LIST OF CLINICAL TRIALS FOR COMPANION DIAGNOSTICS
           5.2.4 CHALLENGES
                    5.2.4.1 Shortage of trained professionals
                    5.2.4.2 Lack of awareness of companion diagnostics testing
    5.3 IMPACT OF COVID-19 ON COMPANION DIAGNOSTICS MARKET
    5.4 PESSIMISTIC, OPTIMISTIC, AND REALISTIC SCENARIOS
           5.4.1 COMPANION DIAGNOSTICS MARKET
                    FIGURE 25 PESSIMISTIC SCENARIO
                    FIGURE 26 OPTIMISTIC SCENARIO
                    FIGURE 27 REALISTIC SCENARIO
    5.5 PRICING ANALYSIS
           TABLE 5 PRICE OF COMPANION DIAGNOSTICS PRODUCT & SERVICE (2021)
    5.6 PATENT ANALYSIS
           FIGURE 28 PATENT ANALYSIS OF COMPANION DIAGNOSTICS MARKET
    5.7 TRADE ANALYSIS
           5.7.1 TRADE ANALYSIS FOR COMPANION DIAGNOSTICS
                    TABLE 6 IMPORT DATA FOR COMPANION DIAGNOSTICS, BY COUNTRY, 2016–2020 (USD MILLION)
                    TABLE 7 EXPORT DATA FOR COMPANION DIAGNOSTICS, BY COUNTRY, 2016–2020 (USD MILLION)
    5.8 VALUE CHAIN ANALYSIS
           FIGURE 29 MAJOR VALUE IS ADDED DURING MANUFACTURING & ASSEMBLY PHASE
    5.9 SUPPLY CHAIN ANALYSIS
           FIGURE 30 COMPANION DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
    5.10 ECOSYSTEM ANALYSIS OF COMPANION DIAGNOSTICS MARKET
           FIGURE 31 COMPANION DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
           5.10.1 ROLE IN ECOSYSTEM
    5.11 PORTER’S FIVE FORCES ANALYSIS
                    TABLE 8 COMPANION DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.11.1 THREAT OF NEW ENTRANTS
           5.11.2 THREAT OF SUBSTITUTES
           5.11.3 BARGAINING POWER OF BUYERS
           5.11.4 BARGAINING POWER OF SUPPLIERS
           5.11.5 DEGREE OF COMPETITION
    5.12 REGULATORY LANDSCAPE
           5.12.1 NORTH AMERICA
                    5.12.1.1 US
                    5.12.1.2 Canada
           5.12.2 EUROPE
           5.12.3 ASIA PACIFIC
                    5.12.3.1 China
                    5.12.3.2 Japan
                    5.12.3.3 India
           5.12.4 LATIN AMERICA
                    5.12.4.1 Brazil
                    5.12.4.2 Mexico
           5.12.5 MIDDLE EAST
    5.13 TECHNOLOGY ANALYSIS
    5.14 PESTLE ANALYSIS
    5.15 TRENDS/DISRUPTIONS IMPACTING THE BUSINESS OF CUSTOMERS
           5.15.1 REVENUE SOURCES ARE SHIFTING TOWARDS TECHNOLOGY-BASED SOLUTIONS DUE TO COVID-19 PANDEMIC
           5.15.2 REVENUE SHIFT FOR COMPANION DIAGNOSTICS MARKET

6 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 82)
    6.1 INTRODUCTION
           TABLE 9 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
           TABLE 10 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
    6.2 ASSAYS, KITS & REAGENTS
           6.2.1 INCREASING VOLUME OF CDX TESTS PERFORMED IN LABORATORIES TO SUPPORT ADOPTION OF ASSAYS & KITS
           TABLE 11 KEY PRODUCTS IN ASSAYS AND KITS, BY COMPANY
           TABLE 12 COMPANION DIAGNOSTIC ASSAYS, KITS& REAGENTS MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
           TABLE 13 COMPANION DIAGNOSTIC ASSAYS, KITS& REAGENTS MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
    6.3 SOFTWARE & SERVICES
           6.3.1 NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTICS TESTS TO SUPPORT MARKET GROWTH
                    TABLE 14 KEY PRODUCTS IN SOFTWARE & SERVICES, BY COMPANY
                    TABLE 15 COMPANION DIAGNOSTIC SOFTWARE & SERVICES MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 16 COMPANION DIAGNOSTIC SOFTWARE & SERVICES MARKET, BY COUNTRY, 2021–2026 (USD MILLION)

7 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 90)
    7.1 INTRODUCTION
           TABLE 17 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
           TABLE 18 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
    7.2 POLYMERASE CHAIN REACTION (PCR)
           7.2.1 GROWING APPLICATIONS IN PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS TO DRIVE GROWTH
                    TABLE 19 COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR DETECTION OF RAS/BRAF MUTATION
                    TABLE 20 MAJOR PCR TESTS/KITS AVAILABLE
                    TABLE 21 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 22 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2021–2026 (USD MILLION)
    7.3 NEXT-GENERATION SEQUENCING
           7.3.1 EXPECTED TO RECORD HIGHEST CAGR DURING FORECAST PERIOD
                    TABLE 23 MAJOR NGS TESTS/KITS AVAILABLE
                    TABLE 24 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 25 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2021–2026 (USD MILLION)
    7.4 IN SITU HYBRIDIZATION
           7.4.1 INCREASING DEMAND IN SMALL-TUMOR DIAGNOSTICS TO DRIVE GROWTH
                    TABLE 26 MAJOR ISH TESTS/KITS AVAILABLE
                    TABLE 27 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 28 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2021–2026 (USD MILLION)
    7.5 IMMUNOHISTOCHEMISTRY (IHC)
           7.5.1 INCREASING DEMAND FOR USER-FRIENDLY AND COST-EFFECTIVE TECHNOLOGIES TO SUPPORT GROWTH
                    TABLE 29 MAJOR IHC TESTS/KITS AVAILABLE
                    TABLE 30 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 31 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2021–2026 (USD MILLION)
    7.6 OTHER TECHNOLOGIES
           TABLE 32 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017–2020 (USD MILLION)
           TABLE 33 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2026 (USD MILLION)

8 COMPANION DIAGNOSTICS MARKET, BY INDICATION (Page No. - 106)
    8.1 INTRODUCTION
           TABLE 34 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
           TABLE 35 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
    8.2 CANCER
           TABLE 36 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2020 (USD MILLION)
           TABLE 37 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2021–2026 (USD MILLION)
           TABLE 38 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2017–2020 (USD MILLION)
           TABLE 39 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2021–2026 (USD MILLION)
           8.2.1 LUNG CANCER
                    8.2.1.1 Growing demand for effective therapeutic drugs to increase CDX adoption
                               FIGURE 32 GLOBAL LUNG CANCER INCIDENCE, 2012–2030
                               TABLE 40 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2017–2020 (USD MILLION)
                               TABLE 41 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2021–2026 (USD MILLION)
           8.2.2 BREAST CANCER
                    8.2.2.1 Wide prevalence of breast cancer among women contributes to large size of segment
                               TABLE 42 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2030
                               TABLE 43 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2017–2020 (USD MILLION)
                               TABLE 44 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2021–2026 (USD MILLION)
           8.2.3 BLOOD CANCER
                    8.2.3.1 Increasing incidence of disease to boost market
                               TABLE 45 BLOOD CANCER INCIDENCE, BY REGION, 2020 VS. 2030
                               TABLE 46 COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2017–2020 (USD MILLION)
                               TABLE 47 COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2021–2026 (USD MILLION)
           8.2.4 COLORECTAL CANCER
                    8.2.4.1 Rising need for molecular profiling of primary tumors to drive segment growth
                               TABLE 48 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2017–2020 (USD MILLION)
                               TABLE 49 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2021–2026 (USD MILLION)
           8.2.5 OTHER CANCERS
                    TABLE 50 COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 51 COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2021–2026 (USD MILLION)
    8.3 INFECTIOUS DISEASES
           8.3.1 INCREASING AWARENESS OF TARGETED THERAPIES TO PROPEL SEGMENT GROWTH
                    TABLE 52 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 53 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DIESEASES, BY COUNTRY, 2021–2026 (USD MILLION)
    8.4 CARDIOVASCULAR DISEASES
           8.4.1 RISING DEMAND FOR TARGETED THERAPIES TO DRIVE SEGMENT GROWTH
                    TABLE 54 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 55 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2026 (USD MILLION)
    8.5 NEUROLOGICAL DISEASES
           8.5.1 GROWING NUMBER OF ADVANCED TECHNOLOGIES TO BOOST ADOPTION OF COMPANION DIAGNOSTICS
                    TABLE 56 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 57 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021–2026 (USD MILLION)
    8.6 OTHER INDICATIONS
           TABLE 58 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2017–2020 (USD MILLION)
           TABLE 59 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021–2026 (USD MILLION)

9 COMPANION DIAGNOSTICS MARKET, BY END USER (Page No. - 132)
    9.1 INTRODUCTION
           TABLE 60 COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
           TABLE 61 COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
    9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
           9.2.1 INCREASING USE OF CDX IN PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DRIVE MARKET GROWTH
                    TABLE 62 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 63 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2026 (USD MILLION)
    9.3 REFERENCE LABORATORIES
           9.3.1 RISING DEMAND FOR TARGETED THERAPIES TO DRIVE GROWTH
                    TABLE 64 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 65 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2021–2026 (USD MILLION)
    9.4 CONTRACT RESEARCH ORGANIZATIONS
           9.4.1 SIGNIFICANT DEMAND FOR COMPANION DIAGNOSTIC PRODUCTS FOR USE IN THERAPY-RELATED CLINICAL TRIALS
                    TABLE 66 COMPANION DIAGNOSTICS MARKET FOR CRO, BY COUNTRY, 2017–2020 (USD MILLION)
                    TABLE 67 COMPANION DIAGNOSTICS MARKET FOR CRO BY COUNTRY, 2021–2026 (USD MILLION)
    9.5 OTHER END USERS
           TABLE 68 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2017–2020 (USD MILLION)
           TABLE 69 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2026 (USD MILLION)

10 COMPANION DIAGNOSTICS MARKET, BY REGION (Page No. - 142)
     10.1 INTRODUCTION
               TABLE 70 COMPANION DIAGNOSTICS MARKET, BY REGION, 2017–2020 (USD MILLION)
               TABLE 71 COMPANION DIAGNOSTICS MARKET, BY REGION, 2021–2026 (USD MILLION)
     10.2 NORTH AMERICA
               TABLE 72 NUMBER OF NEW CANCER CASES IN NORTH AMERICA IN 2020, BY TYPE OF CANCER
               FIGURE 33 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035
               FIGURE 34 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT
               TABLE 73 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
               TABLE 74 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
               TABLE 75 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
               TABLE 76 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
               TABLE 77 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
               TABLE 78 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
               TABLE 79 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
               TABLE 80 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
               TABLE 81 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
               TABLE 82 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
               TABLE 83 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
               TABLE 84 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.2.1 US
                       10.2.1.1 Increasing use of companion diagnostics for cancer treatment boosts market
                                   TABLE 85 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
                                   TABLE 86 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 87 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 88 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 89 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 90 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 91 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 92 US: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 93 US: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 94 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 95 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.2.2 CANADA
                       10.2.2.1 Increasing government initiatives expected to drive market
                                   TABLE 96 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
                                   TABLE 97 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 98 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 99 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 100 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 101 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 102 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 103 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 104 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 105 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 106 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
     10.3 EUROPE
               FIGURE 35 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035
               TABLE 107 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
               TABLE 108 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
               TABLE 109 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
               TABLE 110 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
               TABLE 111 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
               TABLE 112 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
               TABLE 113 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
               TABLE 114 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
               TABLE 115 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
               TABLE 116 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
               TABLE 117 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
               TABLE 118 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.3.1 GERMANY
                       10.3.1.1 Favorable government policies to drive market
                                   TABLE 119 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
                                   TABLE 120 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 121 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 122 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 123 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 124 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 125 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 126 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 127 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 128 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 129 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.3.2 UK
                       10.3.2.1 Growing life science industry and increasing focus on research to propel market
                                   TABLE 130 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 131 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 132 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 133 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 134 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 135 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 136 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 137 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 138 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 139 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.3.3 SWITZERLAND
                       10.3.3.1 Strong research-oriented pharma industry supports market growth
                                   TABLE 140 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 141 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 142 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 143 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 144 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 145 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 146 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 147 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 148 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 149 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.3.4 FRANCE
                       10.3.4.1 Increasing government funding for research to support market growth
                                   TABLE 150 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 151 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 152 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 153 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 154 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 155 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 156 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 157 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 158 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 159 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.3.5 ITALY
                       10.3.5.1 Growing demand for better and more powerful therapeutics
                                   TABLE 160 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 161 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 162 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 163 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 164 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 165 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 166 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 167 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 168 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 169 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.3.6 SPAIN
                       10.3.6.1 Increasing focus on advancement of personalized medicine to drive market growth
                                   TABLE 170 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 171 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 172 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 173 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 174 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 175 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 176 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 177 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 178 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 179 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.3.7 REST OF EUROPE
                       TABLE 180 ROE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                       TABLE 181 ROE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                       TABLE 182 ROE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                       TABLE 183 ROE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                       TABLE 184 ROE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                       TABLE 185 ROE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                       TABLE 186 ROE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                       TABLE 187 ROE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                       TABLE 188 ROE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
                       TABLE 189 ROE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
     10.4 ASIA PACIFIC
               FIGURE 36 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035
               FIGURE 37 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET SNAPSHOT
               TABLE 190 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
               TABLE 191 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
               TABLE 192 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
               TABLE 193 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
               TABLE 194 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
               TABLE 195 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
               TABLE 196 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
               TABLE 197 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
               TABLE 198 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
               TABLE 199 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
               TABLE 200 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
               TABLE 201 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.4.1 CHINA
                       10.4.1.1 Growing public access to advanced healthcare facilities to drive market
                                   TABLE 202 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 203 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 204 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 205 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 206 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 207 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 208 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 209 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 210 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 211 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.4.2 JAPAN
                       10.4.2.1 Research initiatives supporting market growth
                                   TABLE 212 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
                                   TABLE 213 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 214 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 215 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 216 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 217 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 218 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 219 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 220 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 221 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 222 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.4.3 INDIA
                       10.4.3.1 Increased demand for early cancer diagnosis to support market growth
                                   TABLE 223 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
                                   TABLE 224 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 225 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 226 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 227 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 228 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 229 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 230 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 231 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 232 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 233 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.4.4 AUSTRALIA
                       10.4.4.1 Initiatives to enhance healthcare access and infrastructure for aging population to drive market
                                   TABLE 234 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 235 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 236 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 237 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 238 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 239 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 240 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 241 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 242 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 243 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.4.5 REST OF ASIA PACIFIC
                       TABLE 244 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                       TABLE 245 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                       TABLE 246 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                       TABLE 247 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                       TABLE 248 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                       TABLE 249 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                       TABLE 250 ROAPAC: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                       TABLE 251 ROAPAC: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                       TABLE 252 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
                       TABLE 253 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
     10.5 LATIN AMERICA
               TABLE 254 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
               TABLE 255 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
               TABLE 256 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
               TABLE 257 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
               TABLE 258 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
               TABLE 259 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
               TABLE 260 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
               TABLE 261 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
               TABLE 262 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
               TABLE 263 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
               TABLE 264 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
               TABLE 265 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.5.1 BRAZIL
                       10.5.1.1 Increasing incidence of lifestyle diseases drives market
                                   TABLE 266 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 267 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 268 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 269 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 270 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 271 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 272 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 273 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 274 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 275 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.5.2 MEXICO
                       10.5.2.1 Growing medical tourism to fuel demand for companion diagnostics
                                   TABLE 276 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                                   TABLE 277 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                                   TABLE 278 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                                   TABLE 279 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                                   TABLE 280 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                                   TABLE 281 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                                   TABLE 282 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                                   TABLE 283 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                                   TABLE 284 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
                                   TABLE 285 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
             10.5.3 REST OF LATIN AMERICA
                       TABLE 286 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                       TABLE 287 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                       TABLE 288 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                       TABLE 289 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                       TABLE 290 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                       TABLE 291 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                       TABLE 292 ROLATAM: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                       TABLE 293 ROLATAM: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                       TABLE 294 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
                       TABLE 295 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA
             10.6.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET GROWTH
                       TABLE 296 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2020 (USD MILLION)
                       TABLE 297 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2026 (USD MILLION)
                       TABLE 298 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
                       TABLE 299 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION)
                       TABLE 300 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2020 (USD MILLION)
                       TABLE 301 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021–2026 (USD MILLION)
                       TABLE 302 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017–2020 (USD MILLION)
                       TABLE 303 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021–2026 (USD MILLION)
                       TABLE 304 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2020 (USD MILLION)
                       TABLE 305 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021–2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 270)
     11.1 OVERVIEW
     11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
             11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN COMPANION DIAGNOSTICS MARKET
                       TABLE 306 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANION DIAGNOSTICS MANUFACTURING COMPANIES
     11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
               FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN COMPANION DIAGNOSTICS MARKET (2015-2020)
     11.4 MARKET SHARE ANALYSIS
               FIGURE 39 COMPANION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2020)
               TABLE 307 COMPANION DIAGNOSTICSMARKET: DEGREE OF COMPETITION
     11.5 COMPANY EVALUATION QUADRANT
             11.5.1 LIST OF EVALUATED VENDORS
             11.5.2 STARS
             11.5.3 EMERGING LEADERS
             11.5.4 PERVASIVE PLAYERS
             11.5.5 PARTICIPANTS
                       FIGURE 40 COMPANION DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
     11.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2020)
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
                       FIGURE 41 COMPANION DIAGNOSTICSMARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2020
     11.7 COMPETITIVE BENCHMARKING
             11.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
                       FIGURE 42 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN COMPANION DIAGNOSTICSMARKET
                       TABLE 308 PRODUCT FOOTPRINT OF COMPANIES
                       TABLE 309 REGIONAL FOOTPRINT OF COMPANIES
     11.8 COMPETITIVE SCENARIO
             11.8.1 PRODUCT LAUNCHES & REGULATORY APPROVALS
                       TABLE 310 KEY PRODUCT LAUNCHES
             11.8.2 DEALS
                       TABLE 311 KEY DEALS

12 COMPANY PROFILES (Page No. - 281)
(Business overview, Products offered, Recent developments & MnM View)*
     12.1 KEY PLAYERS
             12.1.1 F. HOFFMANN-LA ROCHE AG
                       TABLE 312 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
                       FIGURE 43 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2020)
             12.1.2 AGILENT TECHNOLOGIES, INC.
                       TABLE 313 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
                       FIGURE 44 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020)
             12.1.3 QIAGEN
                       TABLE 314 QIAGEN: BUSINESS OVERVIEW
                       FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2020)
             12.1.4 THERMO FISHER SCIENTIFIC, INC.
                       TABLE 315 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                       FIGURE 46 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)
             12.1.5 ABBOTT LABORATORIES, INC.
                       TABLE 316 ABBOTT LABORATORIES, INC.: BUSINESS OVERVIEW
                       FIGURE 47 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT (2020)
             12.1.6 ALMAC GROUP
                       TABLE 317 ALMAC GROUP: BUSINESS OVERVIEW
             12.1.7 DANAHER CORPORATION
                       TABLE 318 DANAHER CORPORATION: BUSINESS OVERVIEW
                       FIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
             12.1.8 ILLUMINA, INC.
                       TABLE 319 ILLUMINA, INC.: BUSINESS OVERVIEW
                       FIGURE 49 ILLUMINA, INC.: COMPANY SNAPSHOT (2020)
             12.1.9 BIOMษRIEUX SA
                       TABLE 320 BIOMษRIEUX SA: BUSINESS OVERVIEW
                       FIGURE 50 BIOMษRIEUX SA: COMPANY SNAPSHOT (2020)
             12.1.10 MYRIAD GENETICS, INC.
                       TABLE 321 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW
                       FIGURE 51 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2020)
             12.1.11 SYSMEX CORPORATION
                       TABLE 322 SYSMEX CORPORATION: BUSINESS OVERVIEW
                       FIGURE 52 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020)
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
     12.2 OTHER PLAYERS
             12.2.1 ABNOVA CORPORATION
             12.2.2 GUARDANT HEALTH, INC.
             12.2.3 ICON PLC
             12.2.4 BIOGENEX LABORATORIES, INC.
             12.2.5 INVIVOSCRIBE TECHNOLOGIES
             12.2.6 ARCHERDX, INC.
             12.2.7 NG BIOTECH
             12.2.8 Qฒ SOLUTIONS
             12.2.9 AMOY DIAGNOSTICS CO., LTD.
             12.2.10 ABACUS DIAGNOSTICA OY
             12.2.11 ASURAGEN INC.
             12.2.12 SAGA DIAGNOSTICS
             12.2.13 MESO SCALE DIAGNOSTICS, LLC.
             12.2.14 CREATIVE BIOLABS

13 APPENDIX (Page No. - 323)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 AVAILABLE CUSTOMIZATIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the companion diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.

The following is a breakdown of the primary respondents:

Companion Diagnostics Market  Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the companion diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the companion diagnostics market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Global Companion diagnostics Market Size: Top-Down Approach

Companion Diagnostics Market  Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, segment, and forecast the global companion diagnostics market by product & service, technology, indication, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall companion diagnostics market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze company developments such as product launches, agreements, partnerships, and acquisitions in the companion diagnostics market
  • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Country Information

  • Companion diagnostics market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, Latin America, and Middle East & Africa

Company Profiles

  • Additional five company profiles of players operating in the companion diagnostics market.
Companion Diagnostics Market Size,  Share & Growth Report
Report Code
MD 5463
Published ON
Feb, 2022
Choose License Type
BUY NOW
GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

SEND ME A FREE SAMPLE
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved